Chiesi Secures EC Approval for Pediatric Use of LOJUXTA in Rare Cholesterol Disorder
Event summary
- European Commission approved lomitapide (LOJUXTA®) for pediatric use in Homozygous Familial Hypercholesterolaemia (HoFH) for children aged 5+.
- Approval follows positive CHMP opinion and Phase 3 study showing 53.5% mean reduction in LDL-C at week 24.
- Lomitapide has been approved for adult HoFH patients in the EU since 2013.
- Chiesi Global Rare Diseases is a unit of Chiesi Group, focusing on rare disease therapies.
The big picture
Chiesi's approval for pediatric use of lomitapide addresses a critical unmet need in treating HoFH, a rare genetic disorder that can cause severe cardiovascular damage from an early age. This expansion into pediatric care aligns with broader industry trends towards developing targeted therapies for rare diseases, particularly those affecting younger populations. The approval also underscores Chiesi's strategic focus on rare diseases, reinforcing its commitment to innovative solutions in this niche market.
What we're watching
- Market Expansion
- How Chiesi will leverage this approval to expand its market share in pediatric rare disease treatments.
- Clinical Adoption
- The pace at which pediatricians and specialists adopt lomitapide for HoFH treatment in younger patients.
- Competitive Dynamics
- Whether this approval strengthens Chiesi's position against competitors in the HoFH treatment space.
Related topics